# Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

> **NCT02414269** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 113 (actual)

## Conditions studied

- Malignant Pleural Disease
- Mesothelioma
- Metastases
- Lung Cancer
- Breast Cancer

## Interventions

- **GENETIC:** iCasp9M28z T cell infusions
- **DRUG:** cyclophosphamide
- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT02414269
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-05
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2025-10-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02414269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02414269, "Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02414269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*